Summary of Fabrinet (FN) FY Conference Call - May 15, 2025 Company Overview - **Company**: Fabrinet (FN) - **Industry**: Optical manufacturing and contract manufacturing - **Key Management**: Seamus Grady (CEO), Shava Swerha (CFO) Key Insights and Arguments Customer Behavior and Macro Environment - No observed changes in customer ordering patterns or behaviors, indicating stability in demand despite macroeconomic concerns [3][4] - Majority of products are for infrastructure applications, which are less sensitive to consumer sentiment [4] Revenue Composition and Market Expansion - Approximately 75% of revenue is derived from optical manufacturing, with significant contributions from telecom and datacom sectors [6] - Engagement with AWS and other customers is prompting Fabrinet to expand its capabilities beyond just optical manufacturing [5][6] Contract Manufacturing Strategy - Fabrinet remains focused on contract manufacturing and is not entering the product business, ensuring no competition with existing customers [8][24] - The company is expanding into advanced packaging and system assembly to enhance service offerings [9][10] Datacom Business and Customer Relationships - NVIDIA is the largest customer, with a long-standing relationship that began with Mellanox; significant volumes of transceivers are produced for NVIDIA's products [14][15] - Anticipation of ramping up production for the 1.6T transceivers, with readiness to support new product launches [19][20] Competitive Landscape - The market is growing rapidly, and while competition is increasing, Fabrinet believes there is enough business for all players [30][31] - The company emphasizes its specialized capabilities and low-cost structure as competitive advantages [32] Technology Transitions - Transitioning from 800G to 1.6T is expected to be less impactful on pricing than historically, due to cost-saving measures and increased in-house production [39][41] - Concerns about losing market share in 800G are addressed by the introduction of new versions that will coexist with existing products [46] CPO and Future Technologies - Fabrinet is involved in multiple co-packaged optics (CPO) projects, indicating a strategic position in the evolving optical communication landscape [49][50] - The company sees CPO as a long-term opportunity but acknowledges that it is still in early development stages [50] Financial Outlook and Growth Drivers - Anticipated modest headwinds in Q4 due to simultaneous new product ramps, but expected to resolve quickly as these products gain traction [55][56] - Significant revenue potential from the new Amazon business, with the possibility of it becoming a major customer [65][72] Telecom Market Dynamics - The telecom business is segmented into baseline growth, 400ZR products, and new system wins, all of which are currently experiencing growth [74][78] - The company plans to disclose DCI as a separate category in future reports to provide clearer insights into revenue streams [77] Additional Important Points - The decision to issue warrants to Amazon aligns interests and provides revenue visibility, indicating a strong partnership [65][66] - Fabrinet's manufacturing capabilities are complex and not easily replicable, providing a competitive edge in the face of global tariff concerns [35][36] This summary encapsulates the key points discussed during the conference call, highlighting Fabrinet's strategic positioning, market dynamics, and future growth opportunities.

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $2,810,000, representing a 121% increase year over year compared to $1,270,000 in Q1 2024 [5][21] - Gross margins normalized to 42.4%, compared to 37% in Q4 2024 and 43.6% in Q3 2024 [5][22] - EBITDA loss narrowed to negative $540,000 from negative $840,000 in the same period last year [6][23] - Net loss for Q1 2025 was $710,000, down from a net loss of $850,000 in Q1 2024 [23] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased by 58% year over year, driven by demand from existing customers and new partnerships [5] - Consumer branded products revenue surged by 189% year over year, significantly boosted by the addition of Silly George [5] - The company expects continued growth in both contract manufacturing and consumer products, with a robust pipeline for 2025 [8][11] Market Data and Key Metrics Changes - The company is seeing increased interest in U.S.-made gels due to potential tariff impacts, which may enhance competitiveness against imported products [19] - There is a growing market for hydrogel applications, particularly in laser hair removal, with significant interest from major companies [42] Company Strategy and Development Direction - The company plans to expand its product lines, including new offerings for MetaGel and Cancoderm, and is transitioning Silly George into a broader beauty brand [12][13] - The partnership with Stata is progressing well, with plans for additional product launches in 2025 and 2026 [14] - The company is strategically managing cash and R&D to ensure high ROI while pursuing growth opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving $13,000,000 in revenue and cash flow positivity in 2025 despite external challenges [20] - The company is monitoring tariff situations closely and is prepared to adjust manufacturing strategies if necessary [16][19] - Management expressed confidence in the growth potential of their products and the overall market, despite uncertainties in the broader economic environment [60] Other Important Information - The company has a cash balance of approximately $1,190,000 as of March 31, 2025 [23] - The company has 7,654,537 shares of common stock outstanding as of May 13, 2025 [23] Q&A Session Summary Question: How much revenue was expected from AbbVie, and does the delay affect guidance? - Management indicated that not much revenue was baked in from AbbVie, so the delay should not significantly impact the $13,000,000 projection [25][26] Question: Can you provide details on the product launch with Stata? - The first product is Histosol, a digestive enzyme, with plans for additional digestive enzymes in the future [30] Question: Is there a seasonal improvement expected for Silly George? - Management expects seasonal growth, especially with new product launches planned for Q3 and Q4 [61][62] Question: Will transitioning manufacturing to Texas impact other business lines? - The company has built a new clean room with enough capacity to accommodate potential shifts in manufacturing [35][36] Question: Will the company survive on current cash reserves until EBITDA positive? - Management believes they can manage with current cash reserves until reaching EBITDA positivity [66]